1 Department of Ophthalmology, Marmara University School of Medicine, Istanbul, Turkey.
2 Department of Internal Medicine, Division of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey.
J Ocul Pharmacol Ther. 2019 Jan/Feb;35(1):58-65. doi: 10.1089/jop.2018.0083. Epub 2018 Oct 25.
To investigate factors affecting relapse and remission in patients with Behçet uveitis (BU) in the context of using the interferon alpha2a (IFNα2a) therapy.
Clinical records were reviewed of 32 patients (totaling 54 eyes) presenting with severe BU who had been treated with IFNα2a therapy. Factors influencing relapsing-remitting course of BU during IFNα2a therapy and after the cessation of the agent were evaluated. Possible affecting factors of recurrence were age, gender, duration of the Behçet disease, time elapsed before starting the drug, number of relapses before the starting of IFNα2a, laterality, and presence of panuveitis.
Thirty patients (93.7%) responded to IFNα2a therapy. Annual attack rate before and after IFNα2a treatment was determined to be 4.03 ± 3.19 (attack per year) and 0.58 ± 1.07, respectively (P < 0.001). In univariable statistical evaluation, women tended to have a lower relapse risk than men. Multivariable analyses showed that age was the major factor determining relapse rate, while the effect of gender was not statistically significant (P = 0.196). The other probable influencing factors were not found to be statistically significant (P > 0.05). Increase in visual acuity observed during last examination compared to initial examination was determined to be statistically significant (P = 0.018).
Even if the female gender was evaluated as a good prognostic factor in univariable analyses, it was not assessed as an effective prognostic factor in multivariable analyses. Being aged may be regarded a good prognostic factor on the relapsing-remitting course of patients with BU who were treated with IFNα2a therapy.
探讨干扰素α2a(IFNα2a)治疗贝赫切特葡萄膜炎(BU)患者时,影响疾病复发和缓解的因素。
回顾性分析 32 例(共 54 只眼)接受 IFNα2a 治疗的重度 BU 患者的临床资料。评估 IFNα2a 治疗期间及停药后影响 BU 复发性缓解病程的因素。可能影响复发的因素包括年龄、性别、贝赫切特病病程、开始用药前的时间、开始使用 IFNα2a 前的复发次数、病变侧别、是否存在全葡萄膜炎。
30 例(93.7%)患者对 IFNα2a 治疗有反应。IFNα2a 治疗前后的年发病次数分别为 4.03±3.19(每年发病次数)和 0.58±1.07(每年发病次数),差异有统计学意义(P<0.001)。单变量统计分析显示,女性的复发风险低于男性。多变量分析显示,年龄是决定复发率的主要因素,而性别影响无统计学意义(P=0.196)。其他可能的影响因素无统计学意义(P>0.05)。与初始检查相比,末次检查时视力的提高被认为具有统计学意义(P=0.018)。
即使在单变量分析中,女性被评估为良好的预后因素,但在多变量分析中未被评估为有效的预后因素。年龄可能是接受 IFNα2a 治疗的 BU 患者复发性缓解病程的良好预后因素。